SARS-CoV-2 variants often exhibit immune evasion, necessitating antiviral strategies beyond vaccination. This study presents a papain-like protease (PLpro) inhibitor called YL1004, which exhibits potent, broad-spectrum antiviral activity against wild-type, Delta, and Omicron variants in vitro and in vivo.
- Jinshan Nan
- Huiping Shuai
- Shengyong Yang
